Figure 2.

COL5A1 mutation were associated with ICB treatment response. (a) Kaplan–Meier survival analysis of COL5A1 mutations. (b) Multivariate Cox regression analysis of COL5A1 mutations with age, gender, tumor stage and ICB types were taken into account. (c) Relative abundance of tumor infiltrating leukocytes in COL5A1 mutant-type versus COL5A1 wild-type samples. (d) Tumor mutation load in melanoma samples was compared by COL5A1 mutation status. The notch in the box shows the 95% confidence interval of the median. (e) GSEA pathway enrichment of the top differentially expressed gene sets in COL5A1 mutant versus COL5A1 wild-type group.